Immunotherapy in type 1 diabetes mellitus. Quo vadis?

被引：0

作者：

Fernandez-Balsells, Merce ^{[1
]}

Sojo-Vega, Lidia ^{[1
]}

Ricart-Engel, Wifredo ^{[1
]}

机构：

[1] Hosp Univ Girona Dr Josep Trueta, Serv Endocrinol & Nutr, Girona, Spain

来源：

AVANCES EN DIABETOLOGIA | 2013年 / 29卷 / 06期

关键词：

Diabetes mellitus; Type; 1; Immunotherapy; Autoimmunity;

D O I：

10.1016/j.avdiab.2013.08.001

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The discovery of type 1 diabetes mellitus' (T1DM) autoimmune etiopathogenesis, as well as the effectiveness of diverse immunotherapeutic strategies in T1DM animal models, opened a scenario of pharmacological immuno-intervention in this disease, more than 30 years ago. The aim of current trials that are evaluating these immune therapies at T1DM onset, is to safely modify the natural history of insulin secretion loss in addition to that obtained with intensive insulin treatment. After the great expectations arised at the beginning of the present century with the publication of promising pilot studies, the results of phase III clinical trials have recently been published, with unsatisfactory results. This has again led to a debate on immunological therapies at T1DM onset in the scientific community. (C) 2013 Sociedad Espanola de Diabetes. Published by Elsevier Espana, S.L. All rights reserved.

引用

页码：161 / 168

页数：8

共 40 条

[21] B cells as effectors and regulators of autoimmunity [J].

Marino, Eliana ;

Grey, Shane T. .

AUTOIMMUNITY, 2012, 45 (05) :377-387

[22]

Moran A, 2013, LANCET

[23] Rituximab [J].

Onrust, SV ;

Lamb, HM ;

Balfour, JAB .

DRUGS, 1999, 58 (01) :79-88

[24]

Onrust SV, 1999, DRUGS, V58, P89

[25] Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial [J].

Orban, Tihamer ;

Bundy, Brian ;

Becker, Dorothy J. ;

DiMeglio, Linda A. ;

Gitelman, Stephen E. ;

Goland, Robin ;

Gottlieb, Peter A. ;

Greenbaum, Carla J. ;

Marks, Jennifer B. ;

Monzavi, Roshanak ;

Moran, Antoinette ;

Raskin, Philip ;

Rodriguez, Henry ;

Russell, William E. ;

Schatz, Desmond ;

Wherrett, Diane ;

Wilson, Darrell M. ;

Krischer, Jeffrey P. ;

Skyler, Jay S. .

LANCET, 2011, 378 (9789) :412-419

[26] C-peptide in the natural history of type 1 diabetes [J].

Palmer, Jerry P. .

DIABETES-METABOLISM RESEARCH AND REVIEWS, 2009, 25 (04) :325-328

[27] Cyclosporine nephrotoxicity in type 1 diabetic patients A 7-year follow-up study [J].

Parving, HH ;

Tarnow, L ;

Nielsen, FS ;

Rossing, P ;

Mandrup-Poulsen, T ;

Osterby, R ;

Nerup, J .

DIABETES CARE, 1999, 22 (03) :478-483

[28] Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study [J].

Patterson, Christopher C. ;

Dahquist, Gisela G. ;

Gyurus, Eva ;

Green, Anders ;

Soltesz, Gyula .

LANCET, 2009, 373 (9680) :2027-2033

[29] Antigen-Specific Immunotherapy for Type 1 Diabetes: Maximizing the Potential [J].

Peakman, Mark ;

von Herrath, Matthias .

DIABETES, 2010, 59 (09) :2087-2093

[30] Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function [J].

Pescovitz, Mark D. ;

Greenbaum, Carla J. ;

Krause-Steinrauf, Heidi ;

Becker, Dorothy J. ;

Gitelman, Stephen E. ;

Goland, Robin ;

Gottlieb, Peter A. ;

Marks, Jennifer B. ;

McGee, Paula F. ;

Moran, Antoinette M. ;

Raskin, Philip ;

Rodriguez, Henry ;

Schatz, Desmond A. ;

Wherrett, Diane ;

Wilson, Darrell M. ;

Lachin, John M. ;

Skyler, Jay S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (22) :2143-2152

← 1 2 3 4 →